Our main objective is to provide our partners with a quick and efficient way to translate monoclonal antibodies into competitive differentiated next-generation ADCs with improved characteristics. Our ultimate ambition is to participate actively in the common effort aiming to bring safer and more efficient ADC candidates in clinical trials, ultimately providing new treatment options for cancer patients.